By Karen Roman
Vivani Medical, Inc. (Nasdaq: VANI) announced positive data for NPM-139, its subdermal semaglutide implant for chronic weight management, with expected once or twice-yearly dosing.
The results support the company’s NanoPortal implant for delivery of therapeutic molecules for obesity and type 2 diabetes, Vivani stated.
“This preclinical demonstration of NPM-139 comes on the heels of having rapidly enrolled and successfully implanted an initial group of subjects in LIBERATE-1, our first-in-human study with NPM-115, which we expect will pave the road for NPM-139 as development continues for both programs,” said Adam Mendelsohn, Ph.D., Vivani Medical’s CEO.
Contact:
